Gemcitabine plus Nedaplatin as third-line chemotherapy in patients with metastatic Nasopharyngeal Carcinoma
Objective To evaluate the short term efficacy and toxicity of gemcitabine in combination with nedaplatin as third-line treatment in the patients with metastatic nasopharyngeal carcinoma(NPC). Methods All patients had been previously treated for recurrent disease with a first-line cisplatin-based chemotherapy and a second-line therapy with paclitaxel or docetaxel. Gemcitabine was given on day 1, 8 at a dose of 1000mg/m2 and nedaplatin on days 1 at a dose of 80mg/m2. The chemotherapy was repeated every 3 or 4 weeks. Efficacy and toxicity would be evaluated after the completion of two cycles of chemotherapy. Results No complete response occurred in the patients. Partial remission was observed in 5 patients(23.8%), 9 patients achieved a stable status(42.9%), 7 patients suffered from progressive disease(33.3%). The total response rate(CR+PR) was 23.8% and the disease control rate(CR+PR+SD) was 66.7%. Median time to progression(TTP) was 4.2 months. Hematological toxicities were the predominant side effects with grade 3/4 leukopenia, thrombocytopenia were observed in 52.4%, 57.1% of patients ,respectively, 3 febrile neutropenia occurred. Non-hematological toxicity was mild. Conclusion The combination of gemcitabine and nedaplatin showed a promising results as third-line chemotherapy in patients with metastatic NPC, which merits the further study in a prospective clinical trial.
NETL
NSTL
万方数据
维普
